RxDoctor Payments Data

Sharon Reynolds

Nurse Practitioner · Blairsville, GANPI 1609932110

Payments from drug & device makers

$2,587in general payments, 2019–2025

Across 114 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$315
  • Edwards Lifesciences$283
  • Abbott$277
  • Amgen$267
  • Merck$244
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$224
  • plus $977 from 16 others

What the payments were for

  • Food & beverage$2,587100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,587 in reported general payments places this provider in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$410,209
Medicare patients
597
Services billed
27,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban379$373,829
Repatha SureclickEvolocumab134$96,287
EntrestoSacubitril/Valsartan48$57,218
XareltoRivaroxaban49$52,478
JardianceEmpagliflozin26$29,075
NexletolBempedoic Acid38$15,747
Ranolazine ErRanolazine65$4,029
Metoprolol Succinate259$3,113
Rosuvastatin Calcium280$2,502
Ezetimibe87$1,944
Flecainide Acetate63$1,884
Atorvastatin Calcium222$1,855
Diltiazem 24hr Er (Cd)Diltiazem Hcl118$1,680
Potassium Chloride110$1,402
Losartan Potassium181$1,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$198$373,829379 claims
NovartisEntresto$315$57,21848 claims
Johnson & JohnsonXarelto$85$52,47849 claims
Boehringer IngelheimJardiance$14$29,07526 claims
Esperion Therapeutics, Inc.Nexletol$133$15,74738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Blairsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →